Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 2/2018

01-03-2018 | Original Article

Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II

Authors: Jitka Rybová, Jana Ledvinová, Jakub Sikora, Ladislav Kuchař, Robert Dobrovolný

Published in: Journal of Inherited Metabolic Disease | Issue 2/2018

Login to get access

Abstract

Mucopolysaccharidosis type II (MPSII) is a rare X-linked lysosomal storage disorder caused by mutations in the iduronate-2-sulfatase (IDS) gene (IDS, Xq28). MPSII is characterized by skeletal deformities, hearing loss, airway obstruction, hepatosplenomegaly, cardiac valvular disease, and progressive neurological impairment. At the cellular level, IDS deficiency leads to lysosomal storage of glycosaminoglycans (GAGs), dominated by accumulation of dermatan and heparan sulfates. Human induced pluripotent stem cells (iPSC) represent an alternative system that complements the available MPSII murine model. Herein we report on the reprogramming of peripheral white blood cells from male and female MPSII patients into iPSC using a non-integrating protocol based on the Sendai virus vector system. We differentiated the iPSC lines into IDS deficient and GAG accumulating β-Tubulin III+ neurons, GFAP+ astrocytes, and CNPase+ oligodendrocytes. The lysosomal system in these cells displayed structural abnormalities reminiscent of those previously found in patient tissues and murine IDS deficient neuronal stem cells. Furthermore, quantitative determination of GAGs revealed a moderate increase in GAG levels in IDS deficient neurons and glia. We also tested the effects of recombinant IDS and found that the exogenous enzyme was internalized from the culture media and partially decreased the intracellular GAG levels in iPSC-derived neural cells; however, it failed to completely prevent accumulation of GAGs. In summary, we demonstrate that this human iPSC based model expresses the cellular and biochemical features of MPSII, and thus represents a useful experimental tool for further pathogenesis studies as well as therapy development and testing.
Appendix
Available only for authorised users
Literature
go back to reference All AH, Gharibani P, Gupta S et al (2015) Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors. PLoS One 10:e0116933CrossRefPubMedPubMedCentral All AH, Gharibani P, Gupta S et al (2015) Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors. PLoS One 10:e0116933CrossRefPubMedPubMedCentral
go back to reference Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM (2013) Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem 24:1741–1749CrossRefPubMed Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM (2013) Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem 24:1741–1749CrossRefPubMed
go back to reference Canfield SG, Stebbins MJ, Morales BS et al (2017) An isogenic blood-brain barrier model comprising brain endothelial cells, astrocytes, and neurons derived from human induced pluripotent stem cells. J Neurochem 140:874–888CrossRefPubMed Canfield SG, Stebbins MJ, Morales BS et al (2017) An isogenic blood-brain barrier model comprising brain endothelial cells, astrocytes, and neurons derived from human induced pluripotent stem cells. J Neurochem 140:874–888CrossRefPubMed
go back to reference Cardone M, Polito VA, Pepe S et al (2006) Correction of hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 15:1225–1236CrossRefPubMed Cardone M, Polito VA, Pepe S et al (2006) Correction of hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 15:1225–1236CrossRefPubMed
go back to reference Chen J, Riazifar H, Guan MX, Huang T (2016) Modeling autosomal dominant optic atrophy using induced pluripotent stem cells and identifying potential therapeutic targets. Stem Cell Res Ther 7:2CrossRefPubMedPubMedCentral Chen J, Riazifar H, Guan MX, Huang T (2016) Modeling autosomal dominant optic atrophy using induced pluripotent stem cells and identifying potential therapeutic targets. Stem Cell Res Ther 7:2CrossRefPubMedPubMedCentral
go back to reference Fusar Poli E, Zalfa C, D'Avanzo F et al (2013) Murine neural stem cells model hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved. Cell Death Dis 4:e906CrossRefPubMedPubMedCentral Fusar Poli E, Zalfa C, D'Avanzo F et al (2013) Murine neural stem cells model hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved. Cell Death Dis 4:e906CrossRefPubMedPubMedCentral
go back to reference Gallagher JT (2006) Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem Soc Trans 34:438–441CrossRefPubMed Gallagher JT (2006) Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem Soc Trans 34:438–441CrossRefPubMed
go back to reference Gomes IC, Acquarone M, Maciel Rde M, Erlich RB, Rehen SK (2010) Analysis of pluripotent stem cells by using cryosections of embryoid bodies. J Vis Exp. doi: 10.3791/2344 Gomes IC, Acquarone M, Maciel Rde M, Erlich RB, Rehen SK (2010) Analysis of pluripotent stem cells by using cryosections of embryoid bodies. J Vis Exp. doi: 10.3791/2344
go back to reference Hartree EF (1972) Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 48:422–427CrossRefPubMed Hartree EF (1972) Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 48:422–427CrossRefPubMed
go back to reference Itier JM, Ret G, Viale S et al (2014) Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis 37:1013–1022CrossRefPubMed Itier JM, Ret G, Viale S et al (2014) Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis 37:1013–1022CrossRefPubMed
go back to reference Jakobkiewicz-Banecka J, Gabig-Ciminska M, Kloska A et al (2016) Glycosaminoglycans and mucopolysaccharidosis type III. Front Biosci (Landmark Ed) 21:1393–1409CrossRef Jakobkiewicz-Banecka J, Gabig-Ciminska M, Kloska A et al (2016) Glycosaminoglycans and mucopolysaccharidosis type III. Front Biosci (Landmark Ed) 21:1393–1409CrossRef
go back to reference Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ (2013) The effect of idursulfase on growth in patients with hunter syndrome: data from the hunter outcome survey (HOS). Mol Genet Metab 109:41–48CrossRefPubMed Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ (2013) The effect of idursulfase on growth in patients with hunter syndrome: data from the hunter outcome survey (HOS). Mol Genet Metab 109:41–48CrossRefPubMed
go back to reference de Jong JG, Wevers RA, Liebrand-van Sambeek R (1992) Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 38:803–807PubMed de Jong JG, Wevers RA, Liebrand-van Sambeek R (1992) Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 38:803–807PubMed
go back to reference Meier C, Wismann U, Herschkowitz N, Bischoff A (1979) Morphological observations in the nervous system of prenatal mucopolysaccharidosis II (M. Hunter). Acta Neuropathol 48:139–143CrossRefPubMed Meier C, Wismann U, Herschkowitz N, Bischoff A (1979) Morphological observations in the nervous system of prenatal mucopolysaccharidosis II (M. Hunter). Acta Neuropathol 48:139–143CrossRefPubMed
go back to reference Meng XL, Shen JS, Kawagoe S, Ohashi T, Brady RO, Eto Y (2010) Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc Natl Acad Sci U S A 107:7886–7891CrossRefPubMedPubMedCentral Meng XL, Shen JS, Kawagoe S, Ohashi T, Brady RO, Eto Y (2010) Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc Natl Acad Sci U S A 107:7886–7891CrossRefPubMedPubMedCentral
go back to reference Motas S, Haurigot V, Garcia M et al (2016) CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (hunter syndrome). JCI Insight 1:e86696CrossRefPubMedPubMedCentral Motas S, Haurigot V, Garcia M et al (2016) CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (hunter syndrome). JCI Insight 1:e86696CrossRefPubMedPubMedCentral
go back to reference Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA (2002) Enzyme replacement therapy in mucopolysaccharidosis type II (hunter syndrome): a preliminary report. Acta Paediatr Suppl 91:98–99CrossRefPubMed Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA (2002) Enzyme replacement therapy in mucopolysaccharidosis type II (hunter syndrome): a preliminary report. Acta Paediatr Suppl 91:98–99CrossRefPubMed
go back to reference Muenzer J, Beck M, Eng CM et al (2011) Long-term, open-labeled extension study of idursulfase in the treatment of hunter syndrome. Gen Med: Off J Am Coll Med Gen 13:95–101 Muenzer J, Beck M, Eng CM et al (2011) Long-term, open-labeled extension study of idursulfase in the treatment of hunter syndrome. Gen Med: Off J Am Coll Med Gen 13:95–101
go back to reference Neufeld EF, Muenzer J (2001) The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 3421–3452 Neufeld EF, Muenzer J (2001) The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 3421–3452
go back to reference Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 39:215–224CrossRefPubMed Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 39:215–224CrossRefPubMed
go back to reference Okuyama T, Tanaka A, Suzuki Y et al (2010) Japan Elaprase treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab 99:18–25 Okuyama T, Tanaka A, Suzuki Y et al (2010) Japan Elaprase treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab 99:18–25
go back to reference Patel P, Suzuki Y, Tanaka A et al (2014) Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with hunter syndrome. Mol Gen Metab Rep 1:184–196 Patel P, Suzuki Y, Tanaka A et al (2014) Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with hunter syndrome. Mol Gen Metab Rep 1:184–196
go back to reference Perrimon N, Bernfield M (2001) Cellular functions of proteoglycans--an overview. Semin Cell Dev Biol 12:65–67CrossRefPubMed Perrimon N, Bernfield M (2001) Cellular functions of proteoglycans--an overview. Semin Cell Dev Biol 12:65–67CrossRefPubMed
go back to reference Polito VA, Abbondante S, Polishchuk RS, Nusco E, Salvia R, Cosma MP (2010) Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum Mol Genet 19:4871–4885CrossRefPubMedPubMedCentral Polito VA, Abbondante S, Polishchuk RS, Nusco E, Salvia R, Cosma MP (2010) Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum Mol Genet 19:4871–4885CrossRefPubMedPubMedCentral
go back to reference Russo FB, Cugola FR, Fernandes IR, Pignatari GC, Beltrao-Braga PC (2015) Induced pluripotent stem cells for modeling neurological disorders. World J Transplant 5:209–221CrossRefPubMedPubMedCentral Russo FB, Cugola FR, Fernandes IR, Pignatari GC, Beltrao-Braga PC (2015) Induced pluripotent stem cells for modeling neurological disorders. World J Transplant 5:209–221CrossRefPubMedPubMedCentral
go back to reference Skoog WA, Beck WS (1956) Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood 11:436–454PubMed Skoog WA, Beck WS (1956) Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood 11:436–454PubMed
go back to reference Stacpoole SR, Bilican B, Webber DJ et al (2011) Efficient derivation of NPCs, spinal motor neurons and midbrain dopaminergic neurons from hESCs at 3% oxygen. Nat Protoc 6:1229–1240CrossRefPubMedPubMedCentral Stacpoole SR, Bilican B, Webber DJ et al (2011) Efficient derivation of NPCs, spinal motor neurons and midbrain dopaminergic neurons from hESCs at 3% oxygen. Nat Protoc 6:1229–1240CrossRefPubMedPubMedCentral
go back to reference Tanaka A, Okuyama T, Suzuki Y et al (2012) Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab 107:513–520CrossRefPubMed Tanaka A, Okuyama T, Suzuki Y et al (2012) Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab 107:513–520CrossRefPubMed
go back to reference Varki A (1999) Essentials of glycobiology, vol xvii. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, p 653 Varki A (1999) Essentials of glycobiology, vol xvii. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, p 653
go back to reference Voznyi YV, Keulemans JL, van Diggelen OP (2001) A fluorimetric enzyme assay for the diagnosis of MPS II (hunter disease). J Inherit Metab Dis 24:675–680CrossRefPubMed Voznyi YV, Keulemans JL, van Diggelen OP (2001) A fluorimetric enzyme assay for the diagnosis of MPS II (hunter disease). J Inherit Metab Dis 24:675–680CrossRefPubMed
go back to reference Wiesmann UN, Spycher MA, Meier C, Liebaers I, Herschkowitz N (1980) Prenatal mucopolysaccharidosis II (hunter): a pathogenetic study. Pediatr Res 14:749–756CrossRefPubMed Wiesmann UN, Spycher MA, Meier C, Liebaers I, Herschkowitz N (1980) Prenatal mucopolysaccharidosis II (hunter): a pathogenetic study. Pediatr Res 14:749–756CrossRefPubMed
go back to reference Wraith JE, Scarpa M, Beck M et al (2008) Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277CrossRefPubMed Wraith JE, Scarpa M, Beck M et al (2008) Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277CrossRefPubMed
Metadata
Title
Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II
Authors
Jitka Rybová
Jana Ledvinová
Jakub Sikora
Ladislav Kuchař
Robert Dobrovolný
Publication date
01-03-2018
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 2/2018
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-017-0108-5

Other articles of this Issue 2/2018

Journal of Inherited Metabolic Disease 2/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.